FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134861285> ?p ?o ?g. }

• W2134861285 endingPage "1018" @default.
• W2134861285 startingPage "1008" @default.
• W2134861285 abstract "Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months after receipt of those therapies were administered idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew from the study. The primary end point was the overall rate of response; secondary end points included the duration of response, progression-free survival, and safety.The median age of the patients was 64 years (range, 33 to 87); patients had received a median of four prior therapies (range, 2 to 12). Subtypes of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or without Waldenström's macroglobulinemia (10). The response rate was 57% (71 of 125 patients), with 6% meeting the criteria for a complete response. The median time to a response was 1.9 months, the median duration of response was 12.5 months, and the median progression-free survival was 11 months. Similar response rates were observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were small for some categories. The most common adverse events of grade 3 or higher were neutropenia (in 27% of the patients), elevations in aminotransferase levels (in 13%), diarrhea (in 13%), and pneumonia (in 7%).In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.)." @default.
• W2134861285 created "2016-06-24" @default.
• W2134861285 creator A5001765276 @default.
• W2134861285 creator A5004025497 @default.
• W2134861285 creator A5011011110 @default.
• W2134861285 creator A5011559739 @default.
• W2134861285 creator A5015361329 @default.
• W2134861285 creator A5027453053 @default.
• W2134861285 creator A5040141808 @default.
• W2134861285 creator A5042317118 @default.
• W2134861285 creator A5046049357 @default.
• W2134861285 creator A5046659441 @default.
• W2134861285 creator A5056235620 @default.
• W2134861285 creator A5056946123 @default.
• W2134861285 creator A5058320427 @default.
• W2134861285 creator A5066010864 @default.
• W2134861285 creator A5067716137 @default.
• W2134861285 creator A5069054551 @default.
• W2134861285 creator A5069477380 @default.
• W2134861285 creator A5080630441 @default.
• W2134861285 creator A5081213752 @default.
• W2134861285 creator A5082892912 @default.
• W2134861285 creator A5086354986 @default.
• W2134861285 creator A5089882481 @default.
• W2134861285 date "2014-03-13" @default.
• W2134861285 modified "2023-10-14" @default.
• W2134861285 title "PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma" @default.
• W2134861285 cites W1759167934 @default.
• W2134861285 cites W1904205969 @default.
• W2134861285 cites W1976402300 @default.
• W2134861285 cites W1984147944 @default.
• W2134861285 cites W2007667499 @default.
• W2134861285 cites W2027971058 @default.
• W2134861285 cites W2029409133 @default.
• W2134861285 cites W2037983836 @default.
• W2134861285 cites W2038053631 @default.
• W2134861285 cites W2039175138 @default.
• W2134861285 cites W2054312534 @default.
• W2134861285 cites W2057370954 @default.
• W2134861285 cites W2078948501 @default.
• W2134861285 cites W2082416335 @default.
• W2134861285 cites W2092915615 @default.
• W2134861285 cites W2107990794 @default.
• W2134861285 cites W2116194748 @default.
• W2134861285 cites W2133201432 @default.
• W2134861285 cites W2151963356 @default.
• W2134861285 cites W2152176229 @default.
• W2134861285 cites W2152911354 @default.
• W2134861285 cites W2165948908 @default.
• W2134861285 cites W2171771895 @default.
• W2134861285 cites W2242685318 @default.
• W2134861285 cites W2602086903 @default.
• W2134861285 cites W4248583329 @default.
• W2134861285 cites W68959763 @default.
• W2134861285 doi "https://doi.org/10.1056/nejmoa1314583" @default.
• W2134861285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4039496" @default.
• W2134861285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24450858" @default.
• W2134861285 hasPublicationYear "2014" @default.
• W2134861285 type Work @default.
• W2134861285 sameAs 2134861285 @default.
• W2134861285 citedByCount "932" @default.
• W2134861285 countsByYear W21348612852013 @default.
• W2134861285 countsByYear W21348612852014 @default.
• W2134861285 countsByYear W21348612852015 @default.
• W2134861285 countsByYear W21348612852016 @default.
• W2134861285 countsByYear W21348612852017 @default.
• W2134861285 countsByYear W21348612852018 @default.
• W2134861285 countsByYear W21348612852019 @default.
• W2134861285 countsByYear W21348612852020 @default.
• W2134861285 countsByYear W21348612852021 @default.
• W2134861285 countsByYear W21348612852022 @default.
• W2134861285 countsByYear W21348612852023 @default.
• W2134861285 crossrefType "journal-article" @default.
• W2134861285 hasAuthorship W2134861285A5001765276 @default.
• W2134861285 hasAuthorship W2134861285A5004025497 @default.
• W2134861285 hasAuthorship W2134861285A5011011110 @default.
• W2134861285 hasAuthorship W2134861285A5011559739 @default.
• W2134861285 hasAuthorship W2134861285A5015361329 @default.
• W2134861285 hasAuthorship W2134861285A5027453053 @default.
• W2134861285 hasAuthorship W2134861285A5040141808 @default.
• W2134861285 hasAuthorship W2134861285A5042317118 @default.
• W2134861285 hasAuthorship W2134861285A5046049357 @default.
• W2134861285 hasAuthorship W2134861285A5046659441 @default.
• W2134861285 hasAuthorship W2134861285A5056235620 @default.
• W2134861285 hasAuthorship W2134861285A5056946123 @default.
• W2134861285 hasAuthorship W2134861285A5058320427 @default.
• W2134861285 hasAuthorship W2134861285A5066010864 @default.
• W2134861285 hasAuthorship W2134861285A5067716137 @default.
• W2134861285 hasAuthorship W2134861285A5069054551 @default.
• W2134861285 hasAuthorship W2134861285A5069477380 @default.
• W2134861285 hasAuthorship W2134861285A5080630441 @default.
• W2134861285 hasAuthorship W2134861285A5081213752 @default.
• W2134861285 hasAuthorship W2134861285A5082892912 @default.
• W2134861285 hasAuthorship W2134861285A5086354986 @default.
• W2134861285 hasAuthorship W2134861285A5089882481 @default.
• W2134861285 hasBestOaLocation W21348612851 @default.
• W2134861285 hasConcept C126322002 @default.
• W2134861285 hasConcept C143998085 @default.

• next